Eloxatin for Stage III Colon Cancer
Eloxatin, used in combination with infusional 5-fluorouracil/leucovorin
(5-FU/LV), is indicated for adjuvant treatment of stage III colon cancer in
patients who have undergone complete resection of their primary tumors. The indication is based on an improvement
in disease-free survival, with no demonstrated benefit in overall survival after a median follow-up of 4 years.1
In clinical studies of stage III colon cancer, Eloxatin + infusional 5-FU/LV has demonstrated the following benefits:
- Significant reduction in the risk of recurrence (vs. infusional 5-FU/LV alone):
- 24% reduction in the overall risk of recurrence in patients who have undergone surgery
to remove their primary tumors2
- 8.7% absolute improvement in disease-free survival vs. infusional 5-FU/LV alone
at median 4-year follow-up (minimum 41 months)
- Significant increase in disease-free survival in patients receiving 12 cycles (75.9%
with Eloxatin + infusional 5-FU/LV vs. 69.1% with 5-FU/LV alone [P=0.002]), with
no demonstrated benefit in overall survival after a median follow-up of 4 years:2
-
6.8-month absolute improvement in disease-free survival2
To learn more about Eloxatin’s efficacy and safety in colon cancer, visit Adjuvant Colon Cancer Trial.
Eloxatin for Advanced Colon Cancer
Eloxatin + infusional 5-FU/LV is indicated for treatment of advanced carcinoma of the colon or rectum.
In clinical studies of advanced colorectal cancer, Eloxatin + infusional 5-FU/LV demonstrated the following advantages over irinotecan + bolus 5-FU/LV (IFL):
- Longer median survival
- Increased time-to-tumor progression
- Higher response rate
- Significantly increased overall survival (19.4 months vs. 14.6 months, [P<0.0001]) in patients receiving a median of 10 cycles:3
- 4.8-month absolute improvement in overall survival3
To learn more about Eloxatin’s efficacy and safety in metastatic colorectal cancer (MCRC), visit First-Line MCRC Trial.
Eloxatin and Neurotoxicity
- Neurotoxicity is predictable and manageable in the majority of patients.4
- Persistent neuropathy was generally reversible over time:3
- In MCRC, median time to recovery from grade 3 neurotoxicity was 13 weeks after treatment
withdrawal.
- Although sensory neuropathy was more common in MCRC patients receiving Eloxatin-based
regimens, rates of severe nausea, vomiting, diarrhea, febrile neutropenia and dehydration
were significantly lower than with IFL or irinotecan + Eloxatin (IROX).4
To learn more about Eloxatin and neurotoxicity, visit Neuropathy.
To view Clinical Safety Considerations including Boxed Warning, click here.
References:
- Eloxatin® (oxaliplatin injection) prescribing information, sanofi-aventis.
- André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
- Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol. 2004;22:23-30.
- Haller DG. Safety of oxaliplatin in the treatment of colorectal cancer. Oncology (Williston Park). 2000;14 (suppl 11):15-20.